Novo Nordisk Launches Wegovy Weight-Loss Pill in the U.S.
Novo Nordisk's once-daily Wegovy pill launches in the U.S. at $149/month for self-paying customers, intensifying competition with Eli Lilly in the weight-loss drug market.
/ 20 items
#VKTX↓
Novo Nordisk Wins FDA Approval for Wegovy Weight-Loss Pill, Beating Lilly to Market
Novo Nordisk's Wegovy pill becomes the first FDA-approved oral GLP-1 weight-loss medication, launching January 2026 at $149/month as the Danish drugmaker aims to reclaim market share from Eli Lilly.
Lilly's Oral Weight Loss Pill Maintains Results After Injectables
Eli Lilly's (LLY) orforglipron oral pill successfully maintained weight loss in patients switching from injectable GLP-1 drugs, offering a more convenient obesity treatment option with FDA decision expected early 2026.
Structure Therapeutics' Obesity Pill Shows Promising Weight Loss Results, Shares Surge
Structure Therapeutics' (GPCR) experimental obesity pill aleniglipron delivers up to 15.3% weight loss in clinical trials, positioning it as a competitive alternative to Eli Lilly's oral treatment with shares more than doubling on promising Phase 2 results.
Viking Therapeutics Stock Soars: Major Price Target Increases from Wall Street
Morgan Stanley, Cantor Fitzgerald, and BTIG raise Viking Therapeutics (VKTX) price targets to $102-$125, citing accelerated obesity trials and upcoming FDA meeting for oral treatment.
Trump Vows Sharp Cut to Ozempic Price, Sending Novo Nordisk Shares Tumbling
President Trump signaled major price reductions for Novo Nordisk's Ozempic, potentially lowering costs to $150. This announcement, made amid ongoing drug price negotiations, caused significant drops in pharma stock prices.